À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Question clinique
Is fractional carbon dioxide vaginal laser treatment effective for reducing postmenopausal vaginal symptoms?
L’Essentiel
OVERUSE ALERT: Despite widespread global uptake of this procedure based on early observational case series reports (and effective marketing), this randomized controlled trial found no benefit of fractional CO2 vaginal laser treatment compared with sham treatment in reducing postmenopausal vaginal symptoms. 1b
Référence
Plan de l'etude: Randomized controlled trial (double-blinded)
Financement: Foundation
Cadre: Outpatient (specialty)
Sommaire
Early observational studies report a 75% to 100% reduction in postmenopausal vaginal symptoms after fractional carbon dioxide (CO2) laser treatment. These investigators identified 85 women who were 18 years or older; amenorrheic for at least 12 months; and experiencing 1 or more vaginal symptoms, including dyspareunia, burning, itching, or severe dryness. After discontinuing the use of vaginal estrogen for at least 6 months, eligible women randomly received (concealed allocation assignment) 3 treatments, 1 month apart per standard recommendations and standard settings, of either fractional CO2 laser treatment or sham treatment with a similar device set at minimal energy setting with no tissue effect. Visual and auditory effects from the laser were similar between the groups. The individuals who assessed symptoms using previously validated symptom scoring tools remained masked to treatment group assignment. Complete follow-up occurred for 88.4% of participants in the laser group and 95.2% of those in the sham group at 12 months. Using intention-to-treat analysis, no significant group differences occurred between baseline and 12 months in changes in symptom scores, including the most severe symptoms, or quality of life, including sexual activity rates and quality scores. Similarly, no significant group differences occurred in the percentage of participants reporting a 50% or greater reduction in severe symptoms scores.
Reviewer
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC